NCT06789692 Reduce Tobacco Use in People Living With HIV in Switzerland
| NCT ID | NCT06789692 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Basel, Switzerland |
| Condition | HIV |
| Study Type | INTERVENTIONAL |
| Enrollment | 972 participants |
| Start Date | 2025-02-20 |
| Primary Completion | 2027-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 972 participants in total. It began in 2025-02-20 with a primary completion date of 2027-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this trial is to test the effectiveness of offering a menu of different tobacco smoking substitutional products (e-cigarettes, nicotine pouches, nicotine patches in addition to usual of care) for smokers in the SHCS (Swiss HIV Cohort Study) in achieving self-reported 7-day tobacco cigarette abstinence at 6 months.
Eligibility Criteria
Inclusion Criteria: * Signed informed consent for the data collection and participation in the SHCS (Cohort consent). * Signed informed consent to be randomized to future interventions (Randomization consent). * Age 18 years or older. * Smoked one or more tobacco cigarettes per day (smoking status = yes) at the time of enrolment. Exclusion Criteria: * Currently using e-cigarettes or nicotine pouches or nicotine patches. * Pregnant women.
Contact & Investigator
Matthias Briel, Prof.
PRINCIPAL INVESTIGATOR
University Hospital, Basel, Switzerland
Frequently Asked Questions
Who can join the NCT06789692 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying HIV. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06789692 currently recruiting?
Yes, NCT06789692 is actively recruiting participants. Contact the research team at matthias.briel@usb.ch for enrollment information.
Where is the NCT06789692 trial being conducted?
This trial is being conducted at Basel, Switzerland, Bern, Switzerland, Sankt Gallen, Switzerland, Lausanne, Switzerland and 3 additional locations.
Who is sponsoring the NCT06789692 clinical trial?
NCT06789692 is sponsored by University Hospital, Basel, Switzerland. The principal investigator is Matthias Briel, Prof. at University Hospital, Basel, Switzerland. The trial plans to enroll 972 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.